Interstitial Lung Diseases
Conditions
Keywords
Cardiac fibrosis, Lung interstitial fibrosis
Brief summary
Interstitial lung diseases (ILDs) are common chronic disease characterized by high mortality and morbidity, also linked to cardiovascular implication. Cardiovascular complications, occur early in idiopathic pulmonary fibrosis (IPF) and other ILDs without anysymptoms. Symptoms are often misinterpreted and diagnosis delayed to irreversible stages of cardiac dysfunction. Mechanism of cardiac damage, the main cause of mortality, are heterogeneous raging from ischemic heart disease, acceleration of atherosclerosis, to right ventricle dysfunction secondary, to pulmonary hypertension. So an early recognition and accurate staging are fundamental to avoid disease progression and improve outcomes. The identification of a single non-invasive imaging modality able to simultaneously characterize in an accurate and quantitative way the entity of lung and cardiac damage in patients affected by ILD would be useful to improve risk stratification and to guide treatment.
Interventions
None listed
Sponsors
IRCCS San Raffaele
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
• Adult subjects (\>18 y.o.) with previously known ILD or high likelihood for having ILD including CTD diagnosis since at least 5 years before the project starts in order to increase the prevalence of ILD \[2\] who signed an Informed Consent authorizing data collection.
Exclusion criteria
* Subjects with active infectious disease; * known CAD; * history of previous percutaneous or surgical revascularization; * known cardiomyopathy; * previous heart failure; * presence of cardiac devices (prosthetic valve, ICD, PM, ICD-CRT, LVAD) * previous or active neoplasia; * pregnancy and breastfeeding; * allergy to iodine contrast agent; * claustrophobia; * glomerular filtration rate \< 30mL/min * impossibility to lay down or breath old * absence of informed consent signed
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| a low dose image protocol able to characterize ILD related lung parenchyma alteration and new quantitative imaging biomarkers of lung disease severity | months 2-12 |
Secondary
| Measure | Time frame |
|---|---|
| the prevalence and the spectrum of cardiac disease (ischemic heart disease, cardiac remodelling and dysfunction in patients with ILD) and the relationship between severity of lung involvement and cardiac injury | months 3-16 |
| a CT based multiparametric algorithm for risk stratification of patients with ILD | months 19-24 |
Countries
Italy
Contacts
Primary ContactAnna Palmisano
Backup ContactAntonio Esposito Esposito
Outcome results
None listed